

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

L6 39 SEA FILE=REGISTRY SUB=L3 CSS FUL L4

100.0% PROCESSED 62837 ITERATIONS
SEARCH TIME: 00.00.10

39 ANSWERS

=> d his l6-

(FILE 'REGISTRY' ENTERED AT 08:48:29 ON 23 JUL 1999)
L6 39 S L4 CSS FUL SUB=L3
SAV L6 GERSTL139/A

FILE 'HCAOLD' ENTERED AT 08:52:22 ON 23 JUL 1999
L7 0 S L6


FILE 'HCAPLUS' ENTERED AT 08:52:26 ON 23 JUL 1999
L8 4 S L6

FILE 'USPATFULL' ENTERED AT 08:52:29 ON 23 JUL 1999
L9 0 S L6

FILE 'REGISTRY' ENTERED AT 08:52:38 ON 23 JUL 1999

=> d ide can tot l6

L6 ANSWER 1 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-63-9 REGISTRY
CN Benzeneacetic acid, 2-[[2-fluoro-6-(trifluoromethyl)phenyl]amino]-5-methyl-
(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C16 H13 F4 N O2
SR CA
LC STN Files: CA, CAPLUS




1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502

L6 ANSWER 2 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-62-8 REGISTRY
CN Benzeneacetic acid, 2-[[2-fluoro-6-(trifluoromethyl)phenyl]amino]-5-methyl-
, 1-methylethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD


MF C19 H19 F4 N O2
 SR CA
 LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502

L6 ANSWER 3 OF 39 REGISTRY COPYRIGHT 1999 ACS
 RN 220991-60-6 REGISTRY
 CN Benzeneacetic acid, 5-ethyl-2-[(2,3,5,6-tetrafluorophenyl)amino]-,
 monosodium salt (9CI) (CA INDEX NAME)
 MF C16 H13 F4 N O2 . Na
 SR CA
 LC STN Files: CA, CAPLUS
 CRN (220991-32-2)




● Na

1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 4 OF 39 REGISTRY COPYRIGHT 1999 ACS
 RN 220991-48-0 REGISTRY
 CN Benzeneacetic acid, 2-[[2,4-dichloro-6-(trifluoromethyl)phenyl]amino]-5-
 methyl- (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C16 H12 Cl2 F3 N O2
 SR CA
 LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 5 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-47-9 REGISTRY
CN Benzeneacetic acid, 5-ethyl-2-[(2,3,5,6-tetrafluorophenyl)amino]-, 1-carboxy-1-methylethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C20 H19 F4 N O4
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 6 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-46-8 REGISTRY
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl-, carboxymethyl ester (9CI) (CA INDEX NAME)
MF C17 H15 Cl F N O4
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 7 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-45-7 REGISTRY
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-5-methyl-, carboxymethyl ester (9CI) (CA INDEX NAME)
MF C17 H15 Cl2 N O4
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502

L6 ANSWER 8 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-44-6 REGISTRY
CN Benzeneacetic acid, 2-[(2,4-dichloro-6-fluorophenyl)amino]-5-methyl-, carboxymethyl ester (9CI) (CA INDEX NAME)
MF C17 H14 Cl2 F N O4
SR CA
LC STN Files: CA, CAPLUS




1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502

L6 ANSWER 9 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-43-5 REGISTRY
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-ethyl-, carboxymethyl ester (9CI) (CA INDEX NAME)
MF C18 H17 Cl F N O4
SR CA


LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 10 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-42-4 REGISTRY
CN Benzeneacetic acid, 2-[(2,4-dichloro-6-fluorophenyl)amino]-5-ethyl-,
carboxymethyl ester (9CI) (CA INDEX NAME)
MF C18 H16 Cl2 F N O4
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 11 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-41-3 REGISTRY
CN Benzeneacetic acid, 2-[(2-chloro-4,6-difluorophenyl)amino]-5-ethyl-,
carboxymethyl ester (9CI) (CA INDEX NAME)
MF C18 H16 Cl F2 N O4
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 12 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-40-2 REGISTRY
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-5-ethyl-, carboxymethyl ester (9CI) (CA INDEX NAME)
MF C18 H17 Cl2 N O4
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 13 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-39-9 REGISTRY
CN Benzeneacetic acid, 2-[(2,4-dichloro-6-methylphenyl)amino]-5-ethyl-, carboxymethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C19 H19 Cl2 N O4
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 14 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-38-8 REGISTRY
CN Benzeneacetic acid, 5-ethyl-2-[(2,3,5,6-tetrafluorophenyl)amino]-, carboxymethyl ester (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H15 F4 N O4
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502

L6 ANSWER 15 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-37-7 REGISTRY
CN Benzeneacetic acid, 2-[(2-chloro-6-fluoro-4-hydroxyphenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)
MF C15 H13 Cl F N O3
SR CA
LC STN Files: CA, CAPLUS




1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502

L6 ANSWER 16 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-36-6 REGISTRY
CN Benzeneacetic acid, 2-[(2-chloro-4-fluoro-6-methylphenyl)amino]-5-ethyl- (9CI) (CA INDEX NAME)


FS 3D CONCORD
 MF C17 H17 Cl F N O2
 SR CA
 LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 17 OF 39 REGISTRY COPYRIGHT 1999 ACS
 RN 220991-35-5 REGISTRY
 CN Benzenecetic acid, 2-[(2,4-difluoro-6-methylphenyl)amino]-5-ethyl- (9CI)
 (CA INDEX NAME)
 FS 3D CONCORD
 MF C17 H17 F2 N O2
 SR CA
 LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 18 OF 39 REGISTRY COPYRIGHT 1999 ACS
 RN 220991-34-4 REGISTRY
 CN Benzenecetic acid, 2-[(4-chloro-2-fluoro-6-methylphenyl)amino]-5-ethyl-
 (9CI) (CA INDEX NAME)
 FS 3D CONCORD
 MF C17 H17 Cl F N O2
 SR CA
 LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 19 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-33-3 REGISTRY
CN Benzeneacetic acid, 2-[(2,4-dichloro-6-methylphenyl)amino]-5-ethyl- (9CI)
(CA INDEX NAME)
FS 3D CONCORD
MF C17 H17 Cl2 N O2
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502

L6 ANSWER 20 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-32-2 REGISTRY
CN Benzeneacetic acid, 5-ethyl-2-[(2,3,5,6-tetrafluorophenyl)amino]- (9CI)
(CA INDEX NAME)
FS 3D CONCORD
MF C16 H13 F4 N O2
CI COM
SR CA
LC STN Files: CA, CAPLUS




1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502

L6 ANSWER 21 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-31-1 REGISTRY
CN Benzeneacetic acid, 2-[(2,4-dichloro-6-fluorophenyl)amino]-5-ethyl- (9CI)
(CA INDEX NAME)


MF C16 H14 Cl2 F N O2
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 22 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-30-0 REGISTRY
CN Benzenecetic acid, 2-[(2-chloro-4,6-difluorophenyl)amino]-5-ethyl- (9CI)
(CA INDEX NAME)
MF C16 H14 Cl F2 N O2
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 23 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-29-7 REGISTRY
CN Benzenecetic acid, 2-[(4-ethoxy-2,3,5,6-tetrafluorophenyl)amino]-5-ethyl-
(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C18 H17 F4 N O3
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 24 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-28-6 REGISTRY
CN Benzeneacetic acid, 5-ethyl-2-[(2,3,6-trifluorophenyl)amino]- (9CI) (CA
INDEX NAME)
FS 3D CONCORD
MF C16 H14 F3 N O2
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 25 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-27-5 REGISTRY
CN Benzeneacetic acid, 2-[(2-chloro-6-methylphenyl)amino]-5-ethyl- (9CI) (CA
INDEX NAME)
FS 3D CONCORD
MF C17 H18 Cl N O2
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 26 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-26-4 REGISTRY
CN Benzeneacetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-ethyl- (9CI) (CA
INDEX NAME)
MF C16 H15 Cl F N O2
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 27 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-25-3 REGISTRY
CN Benzenecetic acid, 2-[(2-chloro-4-fluorophenyl)amino]-5-methyl-
(9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C16 H15 Cl F N O2
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 28 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-24-2 REGISTRY
CN Benzenecetic acid, 2-[(2,4-dichloro-6-fluorophenyl)amino]-5-methyl- (9CI)
(CA INDEX NAME)
MF C15 H12 Cl2 F N O2
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 29 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-23-1 REGISTRY
CN Benzeneacetic acid, 2-[(2-chloro-4,6-difluorophenyl)amino]-5-methyl- (9CI)
(CA INDEX NAME)
MF C15 H12 Cl F2 N O2
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 30 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-22-0 REGISTRY
CN Benzeneacetic acid, 2-[(2-chloro-6-methylphenyl)amino]-5-methyl- (9CI)
(CA INDEX NAME)
FS 3D CONCORD
MF C16 H16 Cl N O2
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 31 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-21-9 REGISTRY
CN Benzeneacetic acid, 2-[(2,6-dichloro-4-methylphenyl)amino]-5-methyl- (9CI)
(CA INDEX NAME)
MF C16 H15 Cl2 N O2
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 32 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-20-8 REGISTRY
CN Benzenecetic acid, 2-[(2-chloro-6-fluorophenyl)amino]-5-methyl- (9CI)
(CA INDEX NAME)
MF C15 H13 Cl F N O2
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502

L6 ANSWER 33 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-19-5 REGISTRY
CN Benzenecetic acid, 2-[(2,6-dichlorophenyl)amino]-5-methyl-, monosodium
salt (9CI) (CA INDEX NAME)
MF C15 H13 Cl2 N O2 . Na
SR CA
LC STN Files: CA, CAPLUS
CRN (220991-17-3)




● Na

1 REFERENCES IN FILE CA (1967 TO DATE)

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502

L6 ANSWER 34 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-18-4 REGISTRY
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-5-methyl-, monopotassium salt (9CI) (CA INDEX NAME)
MF C15 H13 Cl2 N O2 . K
SR CA
LC STN Files: CA, CAPLUS
CRN (220991-17-3)




● K

1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502

L6 ANSWER 35 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-17-3 REGISTRY
CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)
MF C15 H13 Cl2 N O2
CI COM
SR CA
LC STN Files: CA, CAPLUS




1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502

L6 ANSWER 36 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-16-2 REGISTRY
CN Benzeneacetic acid, 5-methyl-2-[(2,3,5,6-tetrafluorophenyl)amino]- (9CI) (CA INDEX NAME)
FS 3D CONCORD


MF C15 H11 F4 N O2
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502


L6 ANSWER 37 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 220991-15-1 REGISTRY
CN Benzenecetic acid, 2-[(2,4-dichloro-6-methylphenyl)amino]-5-methyl- (9CI)
(CA INDEX NAME)
FS 3D CONCORD
MF C16 H15 Cl2 N O2
SR CA
LC STN Files: CA, CAPLUS



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:209502

L6 ANSWER 38 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 212628-74-5 REGISTRY
CN Benzoic acid, 2-[(4-iodo-2-methylphenyl)amino]-5-methyl- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C15 H14 I N O2
SR CA
LC STN Files: CA, CAPLUS




2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 130:124898

REFERENCE 2: 129:230537

L6 ANSWER 39 OF 39 REGISTRY COPYRIGHT 1999 ACS
RN 40385-17-9 REGISTRY
CN Benzoic acid, 2-[(4,5-dichloro-2-nitrophenyl)amino]-5-methyl- (9CI) (CA
INDEX NAME)
FS 3D CONCORD
MF C14 H10 Cl2 N2 O4
LC STN Files: BEILSTEIN*, CA, CAPLUS
(*File contains numerically searchable property data)



1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 78:17591

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 08:53:19 ON 23 JUL 1999
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1999 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications..

FILE COVERS 1967 - 23 Jul 1999 VOL 131 ISS 4
FILE LAST UPDATED: 23 Jul 1999 (19990723/ED)


This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> d all tot 18

L8 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 1999 ACS
 AN 1999:184221 HCAPLUS
 DN 130:209502
 TI Preparation of 5-alkyl-2-arylamino-phenylacetic acids as COX-2
 cyclooxygenase inhibitors
 IN Fujimoto, Roger Aki; Mcquire, Leslie Wighton; Mugrage, Benjamin Biro; Van
 Duzer, John Henry; Xu, Daqiang
 PA Novartis AG, Switz.; Novartis-Erfindungen Verwaltungs-Gesellschaft m.b.H.
 SO PCT Int. Appl., 44 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC ICM C07C229-42
 ICS A61K032-195
 CC 25-17 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
 Section cross-reference(s): 1
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9911605	A1	19990311	WO 1998-EP5414	19980826
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9895340	A1	19990322	AU 1998-95340	19980826
PRAI	US 1997-57803		19970828		
	US 1997-69837		19970828		
	WO 1998-EP5414		19980826		
OS	MARPAT 130:209502				
GI					



AB The title compds. I [R = Me, Et; R1 = chloro, fluoro; R2 = hydrogen,

fluoro; R3 = hydrogen, fluoro, chloro, Me, Et, methoxy, ethoxy, hydroxy; R4 = hydrogen, fluoro; R5 = chloro, fluoro, trifluoromethyl, methyl], selective COX-2 cyclooxygenase inhibitors, were prepd. IC50 values for I in the COX-2 inhibition assay are as low as 0.005 .mu.M, whereas IC50 values in the COX-1 inhibition assay are > 30 .mu.M. E.g., 5-methyl-2-(2,4-dichloro-6-trifluoromethylanilino)phenylacetic acid was prepd.

ST alkylarylaminophenylacetic acid prepn COX 2 inhibitor; phenylacetic acid alkylaryl amino prepn COX 2 inhibitor; cyclooxygenase inhibitor alkylarylaminophenylacetic acid

IT 39391-18-9

RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)

(2; prepn. of alkyl(aryl amino)phenylacetic acids as COX-2 cyclooxygenase inhibitors)

IT 220991-15-1P 220991-16-2P 220991-17-3P
220991-18-4P 220991-19-5P 220991-20-8P
220991-21-9P 220991-22-0P 220991-23-1P
220991-24-2P 220991-25-3P 220991-26-4P
220991-27-5P 220991-28-6P 220991-29-7P
220991-30-0P 220991-31-1P 220991-32-2P
220991-33-3P 220991-34-4P 220991-35-5P
220991-36-6P 220991-37-7P 220991-38-8P
220991-39-9P 220991-40-2P 220991-41-3P
220991-42-4P 220991-43-5P 220991-44-6P
220991-45-7P 220991-46-8P 220991-47-9P
220991-48-0P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of alkyl(aryl amino)phenylacetic acids as COX-2 cyclooxygenase inhibitors)

IT 59-48-3, Oxindole 394-41-2 589-16-2, 4-Ethylaniline 700-17-4,
2,3,5,6-Tetrafluoroaniline 3282-30-2, Pivaloyl chloride 5437-45-6,
Benzyl 2-bromoacetate 30273-00-8 52548-14-8 75107-16-3 75117-26-9
195191-47-0 220991-61-7

RL: RCT (Reactant)

(prepn. of alkyl(aryl amino)phenylacetic acids as COX-2 cyclooxygenase inhibitors)

IT 150560-61-5P 220991-49-1P 220991-50-4P 220991-51-5P 220991-52-6P
220991-53-7P 220991-54-8P 220991-55-9P 220991-56-0P 220991-57-1P
220991-58-2P 220991-59-3P 220991-60-6P 220991-62-8P
220991-63-9P 220991-64-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(prepn. of alkyl(aryl amino)phenylacetic acids as COX-2 cyclooxygenase inhibitors)

L8 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 1999 ACS

AN 1999:48694 HCAPLUS

DN 130:124898

TI Preparation of 2-(4-bromo or 4-iodo phenyl amino)benzoic acid derivatives as MEK inhibitors

IN Barrett, Stephen Douglas; Bridges, Alexander James; Cody, Donna Reynolds; Doherty, Annette Marian; Dudley, David Thomas; Saltiel, Alan Robert; Schroeder, Mel Conrad; Tecle, Haile

PA Warner-Lambert Company, USA

SO PCT Int. Appl., 67 pp.



CODEN: PIXXD2

DT Patent

LA English
 IC ICM C07C229-58
 ICS C07C237-30; C07C215-68; C07C243-38; C07D257-04; C07D295-12;
 A61K031-195
 CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
 Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9901421	A1	19990114	WO 1998-US13105	19980624
	W:	AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9882626	A1	19990125	AU 1998-82626	19980624
PRAI	US 1997-51433		19970701		
	WO 1998-US13105		19980624		
OS	MARPAT 130:124898				
GI					



AB The title compds. [I; R1 = H, OH, C1-8 alkyl, etc.; R2 = H; R3-R5 = H, OH, halo, etc.; Z = COOR7, tetrazolyl, CONR6R7, etc.; R6, R7 = H, C1-8 alkyl, C2-8 alkenyl, etc.], which are potent inhibitors of MEK and, as such, are effective in treating cancer and other proliferative diseases such as inflammation, psoriasis and restenosis, as well as stroke, heart failure, and immunodeficiency disorders, were prepd. and formulated. Thus, treatment of 2-amino-5-iodotoluene in THF with LDA in THF/heptane/ethylbenzene soln. followed by addn. of 2,4-difluorobenzoic acid in THF afforded II which showed IC50 of 0.019 .mu.M against MEK in vitro.

ST MEK inhibitor bromophenylaminobenzoic acid iodophenylaminobenzoic acid prepn; antiproliferative bromophenylaminobenzoic acid iodophenylaminobenzoic acid prepn; psoriasis bromophenylaminobenzoic acid iodophenylaminobenzoic acid prepn; restenosis bromophenylaminobenzoic acid iodophenylaminobenzoic acid prepn; autoimmune disease bromophenylaminobenzoic acid iodophenylaminobenzoic acid prepn; antiatherosclerotic bromophenylaminobenzoic acid iodophenylaminobenzoic acid prepn; antitumor bromophenylaminobenzoic acid iodophenylaminobenzoic acid prepn; stroke bromophenylaminobenzoic acid iodophenylaminobenzoic acid prepn; heart failure bromophenylaminobenzoic acid iodophenylaminobenzoic acid prepn; hepatomegaly bromophenylaminobenzoic acid iodophenylaminobenzoic acid prepn; cardiomegaly bromophenylaminobenzoic acid iodophenylaminobenzoic acid prepn; antidiabetic bromophenylaminobenzoic acid iodophenylaminobenzoic acid

prepn; Alzheimer's disease bromophenylaminobenzoic acid
iodophenylaminobenzoic acid prepn; cystic fibrosis bromophenylaminobenzoic
acid iodophenylaminobenzoic acid prepn

- IT Liver diseases
(hepatomegaly, treatment of; prepn. of 2-(4-bromo or 4-iodo
phenylamino)benzoic acid derivs. as MEK inhibitors)
- IT Antiatherosclerotics
Antiproliferative agents
Antitumor agents
(prepn. of 2-(4-bromo or 4-iodo phenylamino)benzoic acid derivs. as MEK
inhibitors)
- IT Alzheimer's disease
Antidiabetic agents
Arterial restenosis
Autoimmune diseases
Cystic fibrosis
Heart failure
Psoriasis
Stroke
(treatment of; prepn. of 2-(4-bromo or 4-iodo phenylamino)benzoic acid
derivs. as MEK inhibitors)
- IT 212628-48-3P
RL: BAC (Biological activity or effector, except adverse); RCT (Reactant);
SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
study); PREP (Preparation); USES (Uses)
(prepn. of 2-(4-bromo or 4-iodo phenylamino)benzoic acid derivs. as MEK
inhibitors)
- IT
- | | | | | |
|--------------|---------------------|--------------|--------------|--------------|
| 212628-43-8P | 212628-44-9P | 212628-45-0P | 212628-46-1P | 212628-47-2P |
| 212628-49-4P | 212628-50-7P | 212628-51-8P | 212628-52-9P | 212628-53-0P |
| 212628-54-1P | 212628-55-2P | 212628-56-3P | 212628-57-4P | 212628-58-5P |
| 212628-59-6P | 212628-60-9P | 212628-61-0P | 212628-62-1P | 212628-63-2P |
| 212628-65-4P | 212628-67-6P | 212628-69-8P | 212628-71-2P | 212628-72-3P |
| 212628-73-4P | 212628-74-5P | 212628-75-6P | 212628-76-7P | |
| 212628-77-8P | 212628-78-9P | 212628-79-0P | 212628-80-3P | 212628-81-4P |
| 212628-82-5P | 212628-83-6P | 212628-84-7P | 212628-85-8P | 212628-86-9P |
| 212628-87-0P | 212628-88-1P | 212628-89-2P | 212628-90-5P | 212628-91-6P |
| 212628-92-7P | 212628-93-8P | 212628-94-9P | 212628-95-0P | 212628-96-1P |
| 212628-97-2P | 212628-98-3P | 212628-99-4P | 212629-00-0P | 212629-01-1P |
| 212629-02-2P | 212629-03-3P | 212629-04-4P | 212629-05-5P | 212629-06-6P |
| 212629-07-7P | 212629-08-8P | 212629-09-9P | 212629-10-2P | 212629-11-3P |
| 212629-12-4P | 212629-13-5P | 212629-14-6P | 212629-15-7P | 212629-16-8P |
| 212629-17-9P | 212629-18-0P | 212629-19-1P | 212629-20-4P | 212629-21-5P |
| 212629-22-6P | 212629-23-7P | 212629-24-8P | 212629-25-9P | 212629-26-0P |
| 212629-27-1P | 212629-28-2P | 212629-29-3P | 212629-30-6P | 212629-31-7P |
| 212629-32-8P | 212629-33-9P | 212629-34-0P | 212629-35-1P | 212629-36-2P |
| 212629-37-3P | 212629-38-4P | 212629-39-5P | 212629-40-8P | 212629-41-9P |
| 212629-42-0P | 212629-43-1P | 212629-44-2P | 212629-45-3P | 212629-46-4P |
| 212629-47-5P | 212629-48-6P | 212629-50-0P | 212629-52-2P | 212629-54-4P |
| 212629-56-6P | 212629-58-8P | 212629-60-2P | 212629-62-4P | 212629-64-6P |
| 212629-66-8P | 212629-68-0P | 212629-69-1P | 212629-71-5P | 212629-73-7P |
| 212629-75-9P | 212629-77-1P | 212629-78-2P | 212629-79-3P | 212629-80-6P |
| 212629-81-7P | 212629-82-8P | 212629-83-9P | 212629-84-0P | 212629-85-1P |
| 212629-86-2P | 212629-87-3P | 212629-88-4P | 212629-89-5P | 212629-90-8P |
| 212629-91-9P | 212629-92-0P | 212629-93-1P | 212629-94-2P | 212629-95-3P |
| 212629-98-6P | 212629-99-7P | 212630-00-7P | 212630-03-0P | 212630-04-1P |
| 212630-05-2P | 212630-06-3P | 212630-07-4P | 212630-08-5P | 212630-09-6P |
| 212630-10-9P | 212630-11-0P | 212630-12-1P | 212630-13-2P | 212630-14-3P |
| 212630-15-4P | 212630-16-5P | 212630-17-6P | 212630-18-7P | 212630-19-8P |
| 212630-20-1P | 212630-21-2P | 212630-22-3P | 212630-23-4P | 212630-24-5P |

212630-25-6P 212630-26-7P 212630-27-8P 212630-28-9P 212630-29-0P
212630-30-3P 212630-31-4P 212630-32-5P 212630-33-6P 212630-34-7P
212630-35-8P 212630-36-9P 212630-37-0P 212630-38-1P 212630-39-2P
212630-40-5P 219794-13-5P 219794-21-5P 219796-61-9P 219796-66-4P
219796-67-5P 219796-68-6P 219796-71-1P 219796-73-3P 219796-74-4P
219796-75-5P 219796-76-6P 219796-77-7P 219796-79-9P 219800-81-4P
219800-86-9P 219800-90-5P 219802-06-9P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 2-(4-bromo or 4-iodo phenylamino)benzoic acid derivs. as MEK inhibitors)

IT 142805-58-1, Mek

RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)

(prepn. of 2-(4-bromo or 4-iodo phenylamino)benzoic acid derivs. as MEK inhibitors)

IT 352-33-0, 1-Chloro-4-fluorobenzene 1583-58-0, 2,4-Difluorobenzoic acid
13194-68-8, 2-Amino-5-iodotoluene

RL: RCT (Reactant)

(prepn. of 2-(4-bromo or 4-iodo phenylamino)benzoic acid derivs. as MEK inhibitors)

IT 57381-34-7P 96515-79-6P 212631-82-8P 212631-83-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(prepn. of 2-(4-bromo or 4-iodo phenylamino)benzoic acid derivs. as MEK inhibitors)

L8 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 1999 ACS

AN 1998:603241 HCAPLUS

DN 129:230537

TI Preparation of 2-phenylaminobenzoic acids and its amides as MEK inhibitors for treating or preventing septic shock

IN Bridges, Alexander James

PA Warner Lambert Co., USA

SO PCT Int. Appl., 110 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K031-195

ICS A61K031-165; A61K031-135; A61K031-41; A61K031-495; A61K031-445;
A61K031-40; A61K031-44; A61K031-535; A61K031-38; A61K031-34;
A61K031-18

CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)

Section cross-reference(s): 1

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9837881	A1	19980903	WO 1997-US23389	19971217
	W:	AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, HU, ID, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9856103	A1	19980918	AU 1998-56103	19971217
	ZA 9801578	A	19980902	ZA 1998-1578	19980225
PRAI	US 1997-39270		19970228		
	US 1997-56157		19970819		

WO 1997-US23389 19971217
OS MARPAT 129:230537
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE
PRINT *

AB The title compds. [I and II; R1 = H, OH, C1-8 alkyl, etc.; R2 = H; R3-R5 = H, OH, halo, etc.; Z = CO2R7, tetrazolyl, CONR6R7, etc.; R6, R7 = H, C1-8 alkyl, C2-8 alkenyl, etc.; R8 = H, C1-8 alkyl, aryl, etc.; R9 = H, C1-8 alkyl, C2-8 alkenyl, etc.], useful in treating or preventing septic shock, were prepd. Thus, treatment of 2-amino-5-iodotoluene in THF with LDA/THF/heptane/ethenylbenzene followed by addn. 2,4-difluorobenzoic acid afforded 47% III which showed IC50 of 0.019 .mu.M against MEK in vitro.

ST MEK inhibitor phenylaminobenzoic acid phenylaminobenzamide prepn; septic shock phenylaminobenzoic acid phenylaminobenzamide prepn

IT Septic shock

(prepn. of 2-phenylaminobenzoic acids and its amides as MEK inhibitors for treating or preventing septic shock)

IT 212628-48-3P

RL: BAC (Biological activity or effector, except adverse); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 2-phenylaminobenzoic acids and its amides as MEK inhibitors for treating or preventing septic shock)

IT	167869-21-8P	212628-43-8P	212628-44-9P	212628-45-0P	212628-46-1P
	212628-47-2P	212628-49-4P	212628-50-7P	212628-51-8P	212628-52-9P
	212628-53-0P	212628-54-1P	212628-55-2P	212628-56-3P	212628-57-4P
	212628-58-5P	212628-59-6P	212628-60-9P	212628-61-0P	212628-62-1P
	212628-63-2P	212628-65-4P	212628-67-6P	212628-69-8P	212628-71-2P
	212628-72-3P	212628-73-4P	212628-74-5P	212628-75-6P	
	212628-76-7P	212628-77-8P	212628-78-9P	212628-79-0P	212628-80-3P
	212628-81-4P	212628-82-5P	212628-83-6P	212628-84-7P	212628-85-8P
	212628-86-9P	212628-87-0P	212628-88-1P	212628-89-2P	212628-90-5P
	212628-91-6P	212628-92-7P	212628-93-8P	212628-94-9P	212628-95-0P
	212628-96-1P	212628-97-2P	212628-98-3P	212628-99-4P	212629-00-0P
	212629-01-1P	212629-02-2P	212629-03-3P	212629-04-4P	212629-05-5P
	212629-06-6P	212629-07-7P	212629-08-8P	212629-09-9P	212629-10-2P
	212629-11-3P	212629-12-4P	212629-13-5P	212629-14-6P	212629-15-7P
	212629-16-8P	212629-17-9P	212629-18-0P	212629-19-1P	212629-20-4P
	212629-21-5P	212629-22-6P	212629-23-7P	212629-24-8P	212629-25-9P
	212629-26-0P	212629-27-1P	212629-28-2P	212629-29-3P	212629-30-6P
	212629-31-7P	212629-32-8P	212629-33-9P	212629-34-0P	212629-35-1P
	212629-36-2P	212629-37-3P	212629-38-4P	212629-39-5P	212629-40-8P
	212629-41-9P	212629-42-0P	212629-43-1P	212629-44-2P	212629-45-3P
	212629-46-4P	212629-47-5P	212629-48-6P	212629-50-0P	212629-52-2P
	212629-54-4P	212629-56-6P	212629-58-8P	212629-60-2P	212629-62-4P
	212629-64-6P	212629-66-8P	212629-68-0P	212629-69-1P	212629-71-5P
	212629-73-7P	212629-75-9P	212629-77-1P	212629-78-2P	212629-79-3P
	212629-80-6P	212629-81-7P	212629-82-8P	212629-83-9P	212629-84-0P
	212629-85-1P	212629-86-2P	212629-87-3P	212629-88-4P	212629-89-5P
	212629-90-8P	212629-91-9P	212629-92-0P	212629-93-1P	212629-94-2P
	212629-95-3P	212629-96-4P	212629-97-5P	212629-98-6P	212629-99-7P
	212630-00-7P	212630-03-0P	212630-04-1P	212630-05-2P	212630-06-3P
	212630-07-4P	212630-08-5P	212630-09-6P	212630-10-9P	212630-11-0P
	212630-12-1P	212630-13-2P	212630-14-3P	212630-15-4P	212630-16-5P

212630-17-6P	212630-18-7P	212630-19-8P	212630-20-1P	212630-21-2P
212630-22-3P	212630-23-4P	212630-24-5P	212630-25-6P	212630-26-7P
212630-27-8P	212630-28-9P	212630-29-0P	212630-30-3P	212630-31-4P
212630-32-5P	212630-33-6P	212630-34-7P	212630-35-8P	212630-36-9P
212630-37-0P	212630-38-1P	212630-39-2P	212630-40-5P	212630-41-6P
212630-42-7P	212630-43-8P	212630-44-9P	212630-45-0P	212630-46-1P
212630-47-2P	212630-48-3P	212630-49-4P	212630-50-7P	212630-51-8P
212630-52-9P	212630-53-0P	212630-54-1P	212630-55-2P	212630-56-3P
212630-57-4P	212630-58-5P	212630-59-6P	212630-60-9P	212630-61-0P
212630-62-1P	212630-63-2P	212630-64-3P	212630-65-4P	212630-66-5P
212630-67-6P	212630-68-7P	212630-69-8P	212630-70-1P	212630-71-2P
212630-72-3P	212630-73-4P	212630-74-5P	212630-75-6P	212630-76-7P
212630-77-8P	212630-78-9P	212630-79-0P	212630-80-3P	212630-81-4P
212630-82-5P	212630-83-6P	212630-84-7P	212630-85-8P	212630-86-9P
212630-87-0P	212630-88-1P	212630-89-2P	212630-90-5P	212630-91-6P
212630-92-7P	212630-94-9P	212630-96-1P	212630-98-3P	212630-99-4P
212631-00-0P				

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 2-phenylaminobenzoic acids and its amides as MEK inhibitors for treating or preventing septic shock)

IT	212631-01-1P	212631-02-2P	212631-03-3P	212631-04-4P	212631-05-5P
	212631-06-6P	212631-07-7P	212631-08-8P	212631-09-9P	212631-10-2P
	212631-13-5P	212631-15-7P	212631-25-9P	212631-28-2P	212631-29-3P
	212631-30-6P	212631-31-7P	212631-32-8P	212631-33-9P	212631-34-0P
	212631-35-1P	212631-36-2P	212631-37-3P	212631-38-4P	212631-39-5P
	212631-40-8P	212631-41-9P	212631-42-0P	212631-43-1P	212631-44-2P
	212631-45-3P	212631-46-4P	212631-47-5P	212631-48-6P	212631-49-7P
	212631-50-0P	212631-51-1P	212631-52-2P	212631-53-3P	212631-54-4P
	212631-55-5P	212631-56-6P	212631-57-7P	212631-58-8P	212631-59-9P
	212631-60-2P	212631-61-3P	212631-62-4P	212631-63-5P	212631-64-6P
	212631-65-7P	212631-66-8P	212631-67-9P	212631-68-0P	212631-69-1P
	212631-70-4P	212631-71-5P	212631-72-6P	212631-73-7P	212631-74-8P
	212631-75-9P	212631-76-0P	212631-77-1P	212631-78-2P	212631-79-3P
	212631-80-6P	212631-81-7P			

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of 2-phenylaminobenzoic acids and its amides as MEK inhibitors for treating or preventing septic shock)

IT 146702-84-3, MEK kinase

RL: BSU (Biological study, unclassified); MSC (Miscellaneous); BIOL (Biological study)

(prepn. of 2-phenylaminobenzoic acids and its amides as MEK inhibitors for treating or preventing septic shock)

IT 352-33-0, 1-Chloro-4-fluorobenzene 1583-58-0, 2,4-Difluorobenzoic acid
6723-30-4 13194-68-8, 2-Amino-5-iodotoluene 176317-02-5,
1-Bromo-2,3,4-trifluorobenzene

RL: RCT (Reactant)

(prepn. of 2-phenylaminobenzoic acids and its amides as MEK inhibitors for treating or preventing septic shock)

IT	57381-34-7P	96515-79-6P	212631-82-8P	212631-83-9P	212631-84-0P
	212631-85-1P	212631-86-2P			

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

(prepn. of 2-phenylaminobenzoic acids and its amides as MEK inhibitors for treating or preventing septic shock)

AN 1973:17591 HCAPLUS
 DN 78:17591
 TI Synthesis of 1-substituted 4-nitroacridones
 AU Burdeska, K.; Pugin, A.
 CS Div. Kunstst. Addit., CIBA-GEIGY A.-G., Basel, Switz.
 SO Helv. Chim. Acta (1972), 55(6), 1948-58
 CODEN: HCACAV
 DT Journal
 LA German
 CC 40-6 (Dyes, Fluorescent Whitening Agents, and Photosensitizers)
 Section cross-reference(s): 25, 27
 AB 1-Substituted 4-nitroacridones (I) were prepd. and used as starting compds. for the synthesis of dyes and pigments. Thus, 2,4,5-R(O₂N)2C₆H₂X (R = H, Cl; X = Cl, Br) reacted with anthranilic acids or 3,2-H₂NC₁₀H₆CO₂H in the presence of K₂CO₃ or Na₂CO₃ to give diphenylaminecarboxylic acids (II, R₁ = H, Cl, Me, MeO, AcNH, benzo) in 75-96% yield. Acid-catalyzed cyclization of II gave I in >90% yield. The Cl atom of 1-chloro-4-nitroacridone (I, X = Cl, R = R₁ = H) [20621-51-6] was readily displaced by nucleophilic agents, e.g. KOH, NH₃, PhNH₂, PhOH, or PhSH. I (X = Cl) were dimerized by the Ullmann method to give 4,4'-dinitro-1,1'-biacridones (III) which are high-melting pigments with only moderate lightfastness. Reaction of I (X = Cl, R = H) with o-H₂NC₆H₄CO₂H or o-HSC₆H₄CO₂H and subsequent cyclization formed angular quinacridones (IV, Z = NH) or benzothiopyranoacridinediones (IV, Z = S), resp., both classes of pigments having only moderate fastness to light and migration. 1-Methyl-4-nitroacridone (I, X = Me, R = R₁ = H) [37615-70-6] was prepd. in 95% yield by reaction of o-H₂NC₆H₄CO₂H with 3,4-Br(O₂N)C₆H₃Me followed by cyclization, and was treated with benzaldehydes to give styryl compds. (I, X = PhCH:CH, p-Me₂NC₆H₄CH:CH; R = R₁ = H) with affinity for polyester fiber, and with p-C₆H₄(CHO)₂ to give a bisacridone that had poor lightfastness.
 ST diphenylaminecarboxylic acid deriv; nitroacridone deriv; acridone nitro; dye nitroacridone; pigment nitroacridone; styryl dye; quinacridone dye; polyester dye
 IT Polyester fibers
 RL: USES (Uses)
 (dyes for, acridone derivs. as)
 IT Dyes
 Pigments
 (nitroacridone derivs. as intermediates for)
 IT 20621-51-6P 21810-28-6P 21810-29-7P 21814-51-7P 21814-53-9P
 21814-56-2P 21814-58-4P 21814-60-8P 21814-62-0P 21814-63-1P
 21814-66-4P 21814-67-5P 22171-52-4P 23382-83-4P 37615-70-6P
 40385-05-5P 40385-07-7P 40385-08-8P 40385-09-9P 40385-11-3P
 40385-12-4P 40385-13-5P 40385-14-6P 40385-15-7P 40385-16-8P
40385-17-9P 40385-18-0P 40385-19-1P 40385-28-2P
 40385-31-7P 40385-32-8P 40385-34-0P 40385-35-1P 40385-36-2P
 40385-37-3P 40385-38-4P 40385-39-5P 40385-40-8P 40385-41-9P
 40385-42-0P 40385-43-1P 40385-44-2P 40385-46-4P 40385-47-5P
 40385-48-6P 40385-49-7P 40385-51-1P 40385-52-2P 40385-53-3P
 40385-55-5P 40385-56-6P 40385-57-7P 40499-41-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 IT 610-40-2 40385-54-4
 RL: RCT (Reactant)
 (reaction of, with anthranilic acid)
 IT 118-92-3
 RL: USES (Uses)
 (reaction with chlorodinitrobenzene)

IT 108-98-5 147-93-3
RL: USES (Uses)
(reaction with chloronitroacridone)
IT 623-27-8
RL: USES (Uses)
(reaction with methylnitroacridone)

results broadly paralleled those seen previously for xanthene-4-acetic acids, with 1-, 2- and 7-substitution being dystherapeutic, and substitution at the 5- and 6-positions by lipophilic groups increasing activity. While some analogs were as active as xanthene-4-acetic acids in the histol. assay and gave significant growth delays against colon 38 tumors in vivo, as a class the 9-oxo-9,10-dihydroacridine-4-acetic acids were generally less potent than the xanthene-4-acetic acids.